Research Fellow, Discovery

Alkermes, Inc.

Jörg Bentzien is a Research Fellow in the Modeling and Informatics group at Alkermes, where he is leading the chemistry efforts on an early drug discovery project and providing modeling support throughout the drug discovery organization. Before joining Alkermes Jörg Bentzien worked at Forma Therapeutics, Watertown MA, Boehringer Ingelheim, Ridgefield CT, and Xencor, Monrovia CA. Dr. Bentzien has broad experience in drug discovery working on multiple targets in different disease areas, CNS, Immunology & Inflammation, Cardiometabolic diseases. While at Boehringer Ingelheim he implemented a suite of predictive ADMET models used throughout the Medicinal Chemistry department and pushed for automatically self-updating models. Jörg Bentzien has a Ph.D. in chemistry from the University of Münster, Germany and did post-doctoral studies with Nobel Laureate Arieh Warshel at the University of Southern California.

Latest insights

Fri Mar 13 2020

Did an experimental drug help a U.S. coronavirus patient?

Fri Jan 10 2020

MoneyBall Medicine: Tom Davenport on the Analytics Gap in Healthcare

Wed Dec 18 2019

MoneyBall Medicine – Milind Kamkolkar on Seeing the Forest and the Tr...

Fri Nov 8 2019

Gini Deshpande of NuMedii on Augmented Intelligence for Drug Discovery

Never miss an announcement